Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fomivirsen + ganciclovir
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravitreal, Intravenous, Oral
01
Overview
**fomivirsen + ganciclovir** is a combination therapy composed of fomivirsen, an antisense oligonucleotide, and ganciclovir, a nucleoside analog DNA polymerase inhibitor. Fomivirsen is a 21-base phosphorothioate oligodeoxynucleotide designed to bind specifically to the messenger RNA of immediate-early region 2 of the human cytomegalovirus (CMV), inhibiting viral replication by blocking the synthesis of essential viral proteins. Ganciclovir is a guanine analog that inhibits viral DNA polymerase, suppressing replication of CMV DNA. This combination has been investigated primarily for the treatment of CMV retinitis, particularly in immunocompromised patients such as those with AIDS. The combination is believed to offer an additive antiviral effect relative to either monotherapy, especially in cases that are refractory or resistant to standard treatments.
- Brand names
- Vitavene
- Other names
- fomivirsen sodiumganciclovir sodium
02
Targets
IE2 (HCMV immediate-early protein 2)CMV DNA polymerase (Human cytomegalovirus DNA polymerase)DNA polymerase family
Beyond the preview
Go deeper on fomivirsen + ganciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fomivirsen + ganciclovir.